(IRON) Disc Medicine - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.682m USD | Total Return: 37.2% in 12m
Avg Turnover: 28.4M
Warnings
Share dilution 15.5% YoY
Interest Coverage Ratio -67.1 is critical
Tailwinds
No distinct edge detected
Disc Medicine (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing therapies for serious hematologic disorders. The company’s research centers on modulating biological pathways related to red blood cell formation, specifically targeting heme biosynthesis and iron homeostasis. Its clinical pipeline includes bitopertin for erythropoietic porphyrias, DISC-0974 for anemia related to myelofibrosis and kidney disease, and DISC-3405 for polycythemia vera.
The biotechnology sector often involves high research and development costs and long regulatory timelines before a product reaches commercialization. Disc Medicine utilizes a precision medicine approach to target specific genetic and rare blood diseases, a common business model for small-cap biotech firms seeking orphan drug designations. For deeper insights into these development cycles, investors may find ValueRays analytical tools useful for further research. Headquartered in Watertown, Massachusetts, the company continues to advance several preclinical programs, including DISC-0998 for inflammatory-related anemia.
- Bitopertin clinical trial data readouts drive volatility in erythropoietic protoporphyria market
- FDA regulatory feedback on bitopertin registrational path dictates long-term valuation
- DISC-0974 advancement in myelofibrosis and kidney disease expands addressable patient population
- Cash runway and capital allocation influence stability during clinical-stage development
- Strategic partnerships and licensing agreements impact non-dilutive funding and commercialization prospects
| Net Income: -241.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -12.32 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.27 > 3% & CFO -201.3m > Net Income -241.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 24.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (38.5m) vs 12m ago 15.50% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: -1.64% > 50% (prev 0.0%; Δ -1.64% > 0%) |
| Interest Coverage Ratio: -67.14 > 6 (EBIT TTM -238.6m / Interest Expense TTM 3.55m) |
| A: 0.95 (Total Current Assets 747.5m - Total Current Liabilities 31.1m) / Total Assets 750.2m |
| B: -0.76 (Retained Earnings -573.7m / Total Assets 750.2m) |
| C: -0.33 (EBIT TTM -238.6m / Avg Total Assets 729.7m) |
| D: 11.14 (Book Value of Equity 688.4m / Total Liabilities 61.8m) |
| Altman-Z'' = 13.27 = AAA |
As of June 20, 2026, the stock is trading at USD 70.79 with a total of 1,562,300 shares traded.
Over the past week, the price has changed by +3.98%,
over one month by +10.49%,
over three months by +19.64% and
over the past year by +37.16%.
Disc Medicine has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy IRON.
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 101.6 | 43.5% |
P/B = 3.8958
Revenue TTM = -12.0m USD
EBIT TTM = -238.6m USD
EBITDA TTM = -238.2m USD
Long Term Debt = 29.4m USD (from longTermDebt, last quarter)
Short Term Debt = 419k USD (from shortTermDebt, last quarter)
Debt = 32.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.70m
Net Debt = -697.4m USD (calculated: Debt 32.8m - CCE 730.2m)
Enterprise Value = 1.98b USD (2.68b + Debt 32.8m - CCE 730.2m)
Interest Coverage Ratio = -67.14 (Ebit TTM -238.6m / Interest Expense TTM 3.55m)
EV/FCF = -9.86x (Enterprise Value 1.98b / FCF TTM -201.3m)
FCF Yield = -10.15% (FCF TTM -201.3m / Enterprise Value 1.98b)
WARNING: Negative Revenue TTM = -12.0m
FCF Margin = 1.68k% (FCF TTM -201.3m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Net Margin = 2.02k% (Net Income TTM -241.6m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Gross Margin = unknown ((Revenue TTM -12.0m - Cost of Revenue TTM 350k) / Revenue TTM)
Tobins Q-Ratio = 2.65 (Enterprise Value 1.98b / Total Assets 750.2m)
Interest Expense / Debt = 10.85% (Interest Expense 3.55m / Debt 32.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -188.5m (EBIT -238.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 24.00 (Total Current Assets 747.5m / Total Current Liabilities 31.1m)
Debt / Equity = 0.05 (Debt 32.8m / totalStockholderEquity, last quarter 688.4m)
Debt / EBITDA = 2.93 (negative EBITDA) (Net Debt -697.4m / EBITDA -238.2m)
Debt / FCF = 3.46 (negative FCF - burning cash) (Net Debt -697.4m / FCF TTM -201.3m)
Total Stockholder Equity = 654.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.11% (Net Income -241.6m / Total Assets 750.2m)
RoE = -36.95% (Net Income TTM -241.6m / Total Stockholder Equity 654.0m)
RoCE = -34.92% (EBIT -238.6m / Capital Employed (Equity 654.0m + L.T.Debt 29.4m))
RoIC = -26.20% (negative operating profit) (NOPAT -188.5m / Invested Capital 719.5m)
WACC = 9.83% (E(2.68b)/V(2.71b) * Re(9.85%) + D(32.8m)/V(2.71b) * Rd(10.85%) * (1-Tc(0.21)))
Discount Rate = 9.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 24.37%
[DCF] Fair Price = unknown (Cash Flow -201.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.62 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.77 | Chg30d=-0.05% | Revisions=+9% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-1.86 | Chg30d=-0.26% | Revisions=+0% | Analysts=9
EPS current Year (2026-12-31): EPS=-7.16 | Chg30d=-0.02% | Revisions=+0% | GrowthEPS=-19.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-7.59 | Chg30d=-1.07% | Revisions=+9% | GrowthEPS=-5.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +9%